Phase II and pharmacokinetic study of GL331 in previously treated Chinese gastric cancer patients

Jacqueline Liu, Li Chen, Yee Chao, Anna Li, Chew Wu, Tai Shun Liu, Her Shiah, Jang Chang, Jong Chen, Hsiao Wu, Wei Lin, Chieh Lan, Jacqueline Whang-Peng

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Purpose: A phase II and pharmacokinetic study was designed to assess the efficacy and toxicity profile of an epidophyllotoxin analogue, GL331, in previously treated Chinese gastric cancer patients, with concurrent pharmacokinetic evaluation of the drug's metabolism. Material and methods: GL331 was given at 200 mg/m2 as a daily 3-h infusion for 5 days every 4 weeks. Results: Enrolled in the study were 15 patients. One patient died from neutropenic sepsis before evaluation, one patient did not receive the full dose for reasons unrelated to GL331, nine patients had progressive disease with a median survival of 80 days, and five had stable disease with a median survival of 240 days. Grade 3 and 4 myelosuppression occurred in 10 of the 15 patients, with one death from neutropenic sepsis. This patient's peak GL331 concentration was 16.8 μg/ml, which was high compared to the mean peak drug concentration of 6±4.1 μg/ml. The mean systemic GL331 clearance was 12.1±7.2 l/h per m2, much lower than 23.3±8.2 l/h per m2 found in the phase I trial. Topoisomerase IIα was determined by immunohistochemistry and overexpression was detected in 3 of 11 specimens. Conclusions: GL331 was ineffective at this dose and schedule in this group of patients in spite of adequate blood levels of the drug.

Original languageEnglish
Pages (from-to)425-428
Number of pages4
JournalCancer Chemotherapy and Pharmacology
Volume49
Issue number5
DOIs
Publication statusPublished - May 6 2002
Externally publishedYes

Fingerprint

Pharmacokinetics
Stomach Neoplasms
Pharmaceutical Preparations
Sepsis
Type II DNA Topoisomerase
Metabolism
Drug Evaluation
Survival
Toxicity
GL 331
Blood
Appointments and Schedules
Immunohistochemistry

Keywords

  • Chinese
  • Gastric cancer
  • GL331
  • Refractory
  • Topoisomerase IIα

ASJC Scopus subject areas

  • Oncology
  • Toxicology
  • Pharmacology
  • Cancer Research
  • Pharmacology (medical)

Cite this

Phase II and pharmacokinetic study of GL331 in previously treated Chinese gastric cancer patients. / Liu, Jacqueline; Chen, Li; Chao, Yee; Li, Anna; Wu, Chew; Liu, Tai Shun; Shiah, Her; Chang, Jang; Chen, Jong; Wu, Hsiao; Lin, Wei; Lan, Chieh; Whang-Peng, Jacqueline.

In: Cancer Chemotherapy and Pharmacology, Vol. 49, No. 5, 06.05.2002, p. 425-428.

Research output: Contribution to journalArticle

Liu, J, Chen, L, Chao, Y, Li, A, Wu, C, Liu, TS, Shiah, H, Chang, J, Chen, J, Wu, H, Lin, W, Lan, C & Whang-Peng, J 2002, 'Phase II and pharmacokinetic study of GL331 in previously treated Chinese gastric cancer patients', Cancer Chemotherapy and Pharmacology, vol. 49, no. 5, pp. 425-428. https://doi.org/10.1007/s00280-002-0429-3
Liu, Jacqueline ; Chen, Li ; Chao, Yee ; Li, Anna ; Wu, Chew ; Liu, Tai Shun ; Shiah, Her ; Chang, Jang ; Chen, Jong ; Wu, Hsiao ; Lin, Wei ; Lan, Chieh ; Whang-Peng, Jacqueline. / Phase II and pharmacokinetic study of GL331 in previously treated Chinese gastric cancer patients. In: Cancer Chemotherapy and Pharmacology. 2002 ; Vol. 49, No. 5. pp. 425-428.
@article{19bf88e96e71419cb4eea2503f4ddfc6,
title = "Phase II and pharmacokinetic study of GL331 in previously treated Chinese gastric cancer patients",
abstract = "Purpose: A phase II and pharmacokinetic study was designed to assess the efficacy and toxicity profile of an epidophyllotoxin analogue, GL331, in previously treated Chinese gastric cancer patients, with concurrent pharmacokinetic evaluation of the drug's metabolism. Material and methods: GL331 was given at 200 mg/m2 as a daily 3-h infusion for 5 days every 4 weeks. Results: Enrolled in the study were 15 patients. One patient died from neutropenic sepsis before evaluation, one patient did not receive the full dose for reasons unrelated to GL331, nine patients had progressive disease with a median survival of 80 days, and five had stable disease with a median survival of 240 days. Grade 3 and 4 myelosuppression occurred in 10 of the 15 patients, with one death from neutropenic sepsis. This patient's peak GL331 concentration was 16.8 μg/ml, which was high compared to the mean peak drug concentration of 6±4.1 μg/ml. The mean systemic GL331 clearance was 12.1±7.2 l/h per m2, much lower than 23.3±8.2 l/h per m2 found in the phase I trial. Topoisomerase IIα was determined by immunohistochemistry and overexpression was detected in 3 of 11 specimens. Conclusions: GL331 was ineffective at this dose and schedule in this group of patients in spite of adequate blood levels of the drug.",
keywords = "Chinese, Gastric cancer, GL331, Refractory, Topoisomerase IIα",
author = "Jacqueline Liu and Li Chen and Yee Chao and Anna Li and Chew Wu and Liu, {Tai Shun} and Her Shiah and Jang Chang and Jong Chen and Hsiao Wu and Wei Lin and Chieh Lan and Jacqueline Whang-Peng",
year = "2002",
month = "5",
day = "6",
doi = "10.1007/s00280-002-0429-3",
language = "English",
volume = "49",
pages = "425--428",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "5",

}

TY - JOUR

T1 - Phase II and pharmacokinetic study of GL331 in previously treated Chinese gastric cancer patients

AU - Liu, Jacqueline

AU - Chen, Li

AU - Chao, Yee

AU - Li, Anna

AU - Wu, Chew

AU - Liu, Tai Shun

AU - Shiah, Her

AU - Chang, Jang

AU - Chen, Jong

AU - Wu, Hsiao

AU - Lin, Wei

AU - Lan, Chieh

AU - Whang-Peng, Jacqueline

PY - 2002/5/6

Y1 - 2002/5/6

N2 - Purpose: A phase II and pharmacokinetic study was designed to assess the efficacy and toxicity profile of an epidophyllotoxin analogue, GL331, in previously treated Chinese gastric cancer patients, with concurrent pharmacokinetic evaluation of the drug's metabolism. Material and methods: GL331 was given at 200 mg/m2 as a daily 3-h infusion for 5 days every 4 weeks. Results: Enrolled in the study were 15 patients. One patient died from neutropenic sepsis before evaluation, one patient did not receive the full dose for reasons unrelated to GL331, nine patients had progressive disease with a median survival of 80 days, and five had stable disease with a median survival of 240 days. Grade 3 and 4 myelosuppression occurred in 10 of the 15 patients, with one death from neutropenic sepsis. This patient's peak GL331 concentration was 16.8 μg/ml, which was high compared to the mean peak drug concentration of 6±4.1 μg/ml. The mean systemic GL331 clearance was 12.1±7.2 l/h per m2, much lower than 23.3±8.2 l/h per m2 found in the phase I trial. Topoisomerase IIα was determined by immunohistochemistry and overexpression was detected in 3 of 11 specimens. Conclusions: GL331 was ineffective at this dose and schedule in this group of patients in spite of adequate blood levels of the drug.

AB - Purpose: A phase II and pharmacokinetic study was designed to assess the efficacy and toxicity profile of an epidophyllotoxin analogue, GL331, in previously treated Chinese gastric cancer patients, with concurrent pharmacokinetic evaluation of the drug's metabolism. Material and methods: GL331 was given at 200 mg/m2 as a daily 3-h infusion for 5 days every 4 weeks. Results: Enrolled in the study were 15 patients. One patient died from neutropenic sepsis before evaluation, one patient did not receive the full dose for reasons unrelated to GL331, nine patients had progressive disease with a median survival of 80 days, and five had stable disease with a median survival of 240 days. Grade 3 and 4 myelosuppression occurred in 10 of the 15 patients, with one death from neutropenic sepsis. This patient's peak GL331 concentration was 16.8 μg/ml, which was high compared to the mean peak drug concentration of 6±4.1 μg/ml. The mean systemic GL331 clearance was 12.1±7.2 l/h per m2, much lower than 23.3±8.2 l/h per m2 found in the phase I trial. Topoisomerase IIα was determined by immunohistochemistry and overexpression was detected in 3 of 11 specimens. Conclusions: GL331 was ineffective at this dose and schedule in this group of patients in spite of adequate blood levels of the drug.

KW - Chinese

KW - Gastric cancer

KW - GL331

KW - Refractory

KW - Topoisomerase IIα

UR - http://www.scopus.com/inward/record.url?scp=0036232644&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036232644&partnerID=8YFLogxK

U2 - 10.1007/s00280-002-0429-3

DO - 10.1007/s00280-002-0429-3

M3 - Article

VL - 49

SP - 425

EP - 428

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 5

ER -